0001640455-20-000089.txt : 20200702 0001640455-20-000089.hdr.sgml : 20200702 20200702193540 ACCESSION NUMBER: 0001640455-20-000089 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200626 FILED AS OF DATE: 20200702 DATE AS OF CHANGE: 20200702 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KARSEN PERRY A CENTRAL INDEX KEY: 0001260573 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-37998 FILM NUMBER: 201011638 MAIL ADDRESS: STREET 1: C/O CELGENE CORPORATION STREET 2: 86 MORRIS AVENUE CITY: SUMMIT STATE: NJ ZIP: 07901 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Jounce Therapeutics, Inc. CENTRAL INDEX KEY: 0001640455 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 454870634 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 780 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-259-3840 MAIL ADDRESS: STREET 1: 780 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 4/A 1 wf-form4a_159373292481119.xml FORM 4/A X0306 4/A 2020-06-26 2020-06-29 0 0001640455 Jounce Therapeutics, Inc. JNCE 0001260573 KARSEN PERRY A C/O JOUNCE THERAPEUTICS, INC. 780 MEMORIAL DRIVE CAMBRIDGE MA 02139 1 0 0 0 Stock Option (Right to Buy) 7.58 2020-06-26 4 A 0 15700 0 A 2030-06-26 Common Stock 15700.0 15700 D The original Form 4 filed on June 29, 2020 erroneously reported 13,550 shares of common stock subject to the stock option. This amendment is being filed to disclose the correct number of shares subject to the reported stock option. The option will vest in equal quarterly installments during the four quarters following the grant date, provided that if the Issuer's 2021 annual meeting of stockholders occurs before the one-year anniversary of the grant date, the unvested portion of the option will vest as of the date of such annual meeting, subject in each case to the Reporting Person's continued service on the Issuer's board of directors. /s/ Kim C. Drapkin, Attorney-in-Fact 2020-07-02